773 related articles for article (PubMed ID: 28685762)
1. Opportunities and challenges in phenotypic drug discovery: an industry perspective.
Moffat JG; Vincent F; Lee JA; Eder J; Prunotto M
Nat Rev Drug Discov; 2017 Aug; 16(8):531-543. PubMed ID: 28685762
[TBL] [Abstract][Full Text] [Related]
2. Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches.
Lee JA; Berg EL
J Biomol Screen; 2013 Dec; 18(10):1143-55. PubMed ID: 24080259
[TBL] [Abstract][Full Text] [Related]
3. An industry perspective on drug target validation.
Jones LH
Expert Opin Drug Discov; 2016 Jul; 11(7):623-5. PubMed ID: 27111834
[No Abstract] [Full Text] [Related]
4. Combining label-free cell phenotypic profiling with computational approaches for novel drug discovery.
Fang Y
Expert Opin Drug Discov; 2015 Apr; 10(4):331-43. PubMed ID: 25727255
[TBL] [Abstract][Full Text] [Related]
5. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
Thomas CE; Will Y
Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic screens as a renewed approach for drug discovery.
Zheng W; Thorne N; McKew JC
Drug Discov Today; 2013 Nov; 18(21-22):1067-73. PubMed ID: 23850704
[TBL] [Abstract][Full Text] [Related]
7. Applications of chemogenomic library screening in drug discovery.
Jones LH; Bunnage ME
Nat Rev Drug Discov; 2017 Apr; 16(4):285-296. PubMed ID: 28104905
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in phenotypic drug discovery.
Swinney DC; Lee JA
F1000Res; 2020; 9():. PubMed ID: 32850117
[TBL] [Abstract][Full Text] [Related]
9. How Phenotypic Screening Influenced Drug Discovery: Lessons from Five Years of Practice.
Haasen D; Schopfer U; Antczak C; Guy C; Fuchs F; Selzer P
Assay Drug Dev Technol; 2017; 15(6):239-246. PubMed ID: 28800248
[TBL] [Abstract][Full Text] [Related]
10. Cell and small animal models for phenotypic drug discovery.
Szabo M; Svensson Akusjärvi S; Saxena A; Liu J; Chandrasekar G; Kitambi SS
Drug Des Devel Ther; 2017; 11():1957-1967. PubMed ID: 28721015
[TBL] [Abstract][Full Text] [Related]
11. Next-generation phenotypic screening.
Warchal SJ; Unciti-Broceta A; Carragher NO
Future Med Chem; 2016 Jul; 8(11):1331-47. PubMed ID: 27357617
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic drug discovery: a case for thymosin alpha-1.
Garaci E; Paci M; Matteucci C; Costantini C; Puccetti P; Romani L
Front Med (Lausanne); 2024; 11():1388959. PubMed ID: 38903817
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
Jones HM; Chen Y; Gibson C; Heimbach T; Parrott N; Peters SA; Snoeys J; Upreti VV; Zheng M; Hall SD
Clin Pharmacol Ther; 2015 Mar; 97(3):247-62. PubMed ID: 25670209
[TBL] [Abstract][Full Text] [Related]
14. Personalized medicine and economic evaluation in oncology: all theory and no practice?
Garattini L; Curto A; Freemantle N
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):733-8. PubMed ID: 26289733
[TBL] [Abstract][Full Text] [Related]
15. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
Betz UA
Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic vs. target-based drug discovery for first-in-class medicines.
Swinney DC
Clin Pharmacol Ther; 2013 Apr; 93(4):299-301. PubMed ID: 23511784
[TBL] [Abstract][Full Text] [Related]
17. Precision medicine in oncology drug development: a pharma perspective.
Hollingsworth SJ
Drug Discov Today; 2015 Dec; 20(12):1455-63. PubMed ID: 26482740
[TBL] [Abstract][Full Text] [Related]
18. Target Identification of Compounds from a Cell Viability Phenotypic Screen Using a Bead/Lysate-Based Affinity Capture Platform.
Tang H; Duggan S; Richardson PL; Marin V; Warder SE; McLoughlin SM
J Biomol Screen; 2016 Feb; 21(2):201-11. PubMed ID: 26676096
[TBL] [Abstract][Full Text] [Related]
19. An industrial perspective on the design and development of medicines for older patients.
Page S; Coupe A; Barrett A
Int J Pharm; 2016 Oct; 512(2):352-354. PubMed ID: 27001530
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of target identity and biology: implications for drug discovery and development.
Patel AC
J Biomol Screen; 2013 Dec; 18(10):1164-85. PubMed ID: 24080260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
